Expression of type V secretory phospholipase A2 in myocardial remodelling after infarction

Histopathology

Volumn 47, Issue 3, 2005, Pages 257-267

  Ishikawa, Yukio ^a   Komiyama, K ^b   Masuda, S ^c   Murakami, M ^c   Akasaka, Y ^a   Ito, K ^a   Akishima Fukasawa, Y ^a   Kimura, M ^a   Fujimoto, A ^d   Kudo, I ^c   Ishii, T ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d TOHO UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 2; Immunohistochemistry; in situ hybridization; Myocardial infarction; Myocardial remodelling; Type V secretory phospholipase A2

Indexed keywords

CYCLOOXYGENASE 2; FIBRONECTIN; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; ENZYME RELEASE; FEMALE; GRANULATION TISSUE; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAR FORMATION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; AUTOPSY; CYCLOOXYGENASE 2; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERLEUKIN-1; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PHOSPHOLIPASES A; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR REMODELING;

EID: 24144434707     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02227.x     Document Type: Article

References (40)

1. Mestril R., Dillmann WH. Heat shock proteins and protection against myocardial ischemia. J. Mol. Cell. Cardiol. 1995; 27; 45-52.
2. Mestril R, Chi SH, Sayen MR, O'Reilly K, Dillmann WH. Expression of inducible stress protein 70 in rat heart myogenic cells confers protection against stimulated ischemia-induced injury. J. Clin. Invest. 1994; 93; 759-767.
3. Andres J, Sharma HS, Knoll R et al. Expression of heat shock proteins in the normal and stunned porcine myocardium. Cardiovasc. Res. 1993; 27; 1421-1429.
4. Banai S, Jaklitsch MT, Shou M et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89; 2183-2189.
5. Luo Z, Diaco M, Murohara Y, Ferrara N, Isner JM, Symes JF. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Ann. Thorac. Surg. 1997; 64; 993-998.
6. Yellon DM, Latchmen DS. Stress proteins and myocardial protection. J. Mol. Cell. Cardiol. 1992; 24; 113-124.
7. Banai S, Shweiski D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc. Res. 1994; 28; 1176-1179.
8. Ishikawa Y, Akasaka Y, Ishii T et al. Sequential changes in localization of repair-related proteins (heart shock protein 70, ubiquitin and vascular endothelial growth factor) in the different stages of myocardial infarction. Histopathology 2000; 37; 546-554.
9. Takahashi S, Barry AC, Factor M. Collagen degradation in ischemic rat heart. Biochem. J. 1990; 265; 233-241.
10. Olsen EGJ. Ischemic disease of the myocardium and its complications. In Silver MD ed. Cardiovascular pathology, 2nd edn. Edinburgh: Churchill Livingstone 1991; 671-717.
11. Cleutjens JP, Verluyten MJ, Smits JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am. J. Pathol. 1995; 147; 325-338.
12. Eghbali M, Blumenfeld OO, Seifter S et al. Localization of type I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J. Mol. Cell. Cardiol. 1989; 21; 103-113.
13. Ishikawa Y, Akasaka Y, Ishii T et al. Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodeling after ischemic injury. Histopathology 2003; 42; 43-52.
14. Bai Y, Muragami Y, Obata K, Iwata K, Ooshima A. Immunological properties of monoclonal antibodies to human and rat prolyl 4-hydroxylase. J. Biochem. 1986; 99; 1563-1570.
15. Das DK, Engelman RM, Rousou JA, Breyer RH, Otani H, Lemeshow S. Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion. Am. J. Physiol. 1986; 251; H71-H79.
16. Prasad MR, Popescu LM, Moraru II et al. Role of phospholipase A2 and C in myocardial ischemic reperfusion injury. Am. J. Physiol. 1991; 260; H877-H883.
17. Zalewski A, Goldberg S, Maroko PR. The effects of phospholipase A2 inhibition on experimental infarct size, left ventricular hemodynamics and regional myocardial blood flow. Int. J. Cardiol. 1988; 21; 247-257.
18. Chen J, Engle SJ, Seihamer JJ, Tischfield JA. Cloning and recombinant expression of a novel human low molecular weight Ca2+-dependent phospholipase A2. J. Biol. Chem. 1994; 269; 2365-2368.
19. Valentin E, Singer AG, Ghomashchi F, Lazdunski M, Gelb MH, Lambeau G. Cloning and recombinant expression of human group IIF-secreted phospholipase A2. Biochem. Biophys. Res. Commun. 2000; 279; 223-228.
20. Sawada H, Murakami M, Enomoto A, Shimbara S, Kudo I. Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur. J. Biochem. 1999; 263; 826-833.
21. Murakami M, Shimbara S, Kambe T et al. The function of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2s are functionally redundant and act in concert with cytosolic phospholipase A2. J. Biol. Chem. 1998; 273; 14411-14423.
22. Murakami M, Kambe T, Shimbara S, Kudo I. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J. Biol. Chem. 1999; 274; 3103-3115.
23. Murakami M, Kambe T, Shimbara S et al. Different functional aspects of the group II subfamily (types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J. Biol. Chem. 1999; 274; 31435-31444.
24. Murakami M, Koduri RS, Enomoto A et al. Distinct arachidonate-releasing functions of mammalian secreted phospholipase A2s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms. J. Biol. Chem. 2001; 276; 10083-10096.
25. Ueno N, Murakami M, Tanioka T et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J. Biol. Chem. 2001; 276; 34918-34928.
26. Lodge-Patch I. The aging of cardiac infarcts and its influence on cardiac rupture. Br. Heart. J. 1951; 13; 37-42.
27. Ito M, Ishikawa Y, Kiguchi H et al. Distribution of type V phospholipase A2 expression in human hepatocytes damaged by liver disease. J. Gastroenterol. Hepatol. 2004; 19; 1140-1149.
28. Ishikawa Y, Akasaka Y, Ishii T et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler. Thromb. Vasc. Biol. 1998; 18; 665-672.
29. Chen Y, Dennis EA. Expression and characterization of human group V phospholipase A2. Biochim. Biophys. Acta 1998; 1394; 57-64.
30. De Windt LJ, Willems J, Roemen THM et al. Ischemic-reperfused isolated working mouse hearts: membrane damage and type IIA phospholipase A2. Am. J. Physiol. 2001; 280; H2572-H2580.
31. Bolli R, Shinmura K, Tang XL et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc. Res. 2002; 55; 506-519.
32. Camitta MGW, Gabel SA, Chulada P et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001; 104; 2453-2458.
33. Shekhonin BV, Guriev SB, Irgashev SB, Koteliansky VE. Immunofluorescent identification of fibronectin and fibrinogen/fibrin in experimental myocardial infarction. J. Mol. Cell. Cardiol. 1990; 22; 533-541.
34. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. 1996; 270; H1803-H1811.
35. Baroldi G. Morphologic forms of myocardial necrosis related to myocardial cell function. In Silver MD ed. Cardiovascular pathology, 2nd edn. Edinburgh: Churchill Livingstone 1991; 643-670.
36. Dinarello CA. Interleukin-1β and its biologically related cytokines. Adv. Immunol. 1989; 44; 153-205.
37. Kumar AV, Dee TL, Olsen J, Uretz E, Parrillo JE. Tumor necrosis factor α and interleukin 1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J. Exp. Med. 1996; 183; 949-958.
38. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem. Biophys. Res. Commun. 1995; 208; 582-589.
39. Nijmeijer R, Lagrand WK, Baidoshvili A et al. Secretory type II phospholipase A2 binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc. Res. 2002; 53; 138-146.
40. De Windt LJ, Reneman RS, Van der Vusse GJ, Van Bilsen M. Phospholipase A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques. Mol. Cell Biochem. 1998; 180; 65-73.